Bulletin
Investor Alert

Market Pulse Archives

June 18, 2018, 7:43 a.m. EDT

Ziopharm Oncology shares slide 7% premarket after FDA places clinical hold on cancer trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    ZIOPHARM Oncology Inc. (ZIOP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Ziopharm Oncology Inc. /zigman2/quotes/200291745/composite ZIOP -0.38% said Monday the U.S. Food and Drug Administration has placed a clinical hold on a Phase 1 trial of a treatment for cancer. The trial sought to evaluate CD19-specific CAR-T therapies made with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19 leukemias and lymphomas, the company said in a statement. Ziopharm specializes in developing therapies to treat a range of cancers, using Sleeping Beauty, a non-viral approach to genetically modify chimeric antigen receptor (CAR(+) ) and T-cell receptor (TCR(+) ) T cells, which target specific antigens in blood cancers and neoantigens in solid tumors. "CAR(+) T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch," it said. The FDA is seeking additional information from the company, which is expects to provide in a timely manner, it said. Shares fell 7% premarket on the news, but are up about 3.9% in 2018, matching the S&P 500's /zigman2/quotes/210599714/realtime SPX -0.39% gain.

/zigman2/quotes/200291745/composite
US : U.S.: Nasdaq
$ 3.95
-0.02 -0.38%
Volume: 1.95M
Oct. 18, 2019 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$641.27 million
Rev. per Employee
$3,042
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
2,986.20
-11.75 -0.39%
Volume: 1.99B
Oct. 18, 2019 5:08p
loading...

Get news alerts on ZIOPHARM Oncology Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.